ClinicalTrials.gg

Program

vimseltinib

Also written as “Vimseltinib” and “DCC-3014”.

Its studies are mostly in Synovitis, Pigmented Villonodular · Giant Cell Tumor of Tendon Sheath · Bronchiolitis Obliterans Syndrome, led by Ono Pharmaceutical.

Furthest: phase 3, since Sep 17, 20218 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ono Pharmaceutical85 open or runningphase 3since Sep 17, 2021Feb 20, 2017Dec 2026phase 1 · NCT07744802

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2017First study: phase 2 study in Synovitis, Pigmented VillonodularFirst studyNCT03069469 · 120 enrolled · United States, Australia, Canada and more
  2. Sep 17, 2021Phase 3 study in Giant Cell Tumor of Tendon SheathNCT05059262 · 123 enrolled · United States, Australia, Canada and more
  3. Sep 27, 2024Phase 2 study in Bronchiolitis Obliterans SyndromeNCT06619561 · 48 planned · United States
  4. Aug 28, 20252 phase 1 studies in Healthy ParticipantsNCT07158411, NCT07158398
  5. Apr 13, 2026Phase 1 study in Healthy ParticipantsNCT07539090 · 27 enrolled · United States
  6. Jul 30, 2026Phase 1 study in Healthy Male ParticipantsNCT07744802 · 20 planned · United States
  7. Sep 8, 2026Phase 2 study in Giant Cell Tumor of Tendon SheathNCT07832747 · 18 planned · Japan

Ahead

  1. Dec 2026Primary completion: phase 1 study in Healthy Male ParticipantsNCT07744802
  2. Aug 2028Primary completion: phase 2 study in Synovitis, Pigmented VillonodularNCT03069469
  3. Aug 31, 2028Primary completion: phase 2 study in Giant Cell Tumor of Tendon SheathNCT07832747
  4. Oct 2029Primary completion: phase 2 study in Bronchiolitis Obliterans SyndromeNCT06619561

TargetBeta

CSF1R →read by rule
“An orally bioavailable inhibitor of the tyrosine kinase receptor colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; M-CSFR), ”NCIt, by rule

Other programs on CSF1R

ProgramCompanyFurthest phaseStudies
quizartinibruleDaiichi Sankyophase 322
pimicotinibruleAbbisko Caymanphase 314
axatilimabruleIncytephase 312
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
adrixetinibrulequrient-co-ltdphase 23

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07832747Giant Cell Tumor of Tendon Sheath · Japan2Not yet recruitingAug 31, 202818
NCT07744802Healthy Male Participants · United States1RecruitingDec 202620
NCT07539090Healthy Participants · United States1CompletedOct 8, 202627
NCT07158411Healthy Participants · United States1CompletedJan 30, 202622
NCT07158398Healthy Participants · United States1CompletedDec 8, 202520
NCT06619561Bronchiolitis Obliterans Syndrome · United States2RecruitingOct 202948
NCT05059262Giant Cell Tumor of Tendon Sheath · United States, Australia, Canada and more3Active, not recruitingAug 10, 2023123
NCT03069469Synovitis, Pigmented Villonodular · United States, Australia, Canada and more2Active, not recruitingAug 2028120

How it is read

Names in the registry

  • “Vimseltinib”, 7 entries
  • “DCC-3014”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.